MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced CEO Michael Castagna will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 12:00 PM ET in New York. The company focuses on developing innovative therapeutic products for endocrine and orphan lung diseases. Interested parties can access the live webcast and replay for 14 days via the company’s website. MannKind aims to improve the lives of patients using their advanced inhalation devices and formulations for conditions like diabetes and pulmonary arterial hypertension.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 24^th Annual Global Investment Conference on Tuesday, September 13, 2022 at 12:00 PM ET at the Lotte New York Palace Hotel.    

Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations.  The webcast replay may be accessed at the same location for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.

Contact:        
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

 

FAQ

When will MannKind Corporation CEO Michael Castagna present at the investment conference?

Michael Castagna will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 12:00 PM ET.

What is the purpose of MannKind Corporation's participation in the conference?

MannKind Corporation aims to discuss its innovative therapeutic products for endocrine and orphan lung diseases.

How can I access the MannKind Corporation webcast?

The webcast can be accessed from the Events & Presentations section of MannKind's website and will be available for 14 days.

What is the focus of MannKind Corporation's research and development?

MannKind focuses on developing therapeutic products for serious unmet medical needs, including conditions like diabetes and pulmonary arterial hypertension.

What technologies does MannKind Corporation utilize in its products?

MannKind uses dry-powder formulations and inhalation devices for rapid delivery of medicines to treat various medical conditions.